Innovations and Breakthroughs Shaping OncoDxRx's OncoMRD Technology
With the promise of saving millions of lives, OncoDxRx's OncoMRD is born.
- (1888PressRelease) December 25, 2023 - OncoDxRx’s OncoMRD Program which focuses on monitoring therapy efficacy and recurrence risks associated with solid tumor, are being developed. The program’s contributions to precision oncology so far include identifying potential biomarkers and panels for sensitive and early detection of MRD. This work has been conducted in CLIA/CAP laboratory.
The one-of-a-kind OncoMRD provides a unique advantage – circulating cell-free mRNA (cfmRNA) – for gene expression (GE) signature to better detect, track, treat and monitor many different types of cancers.
A thorough examination of the early decades of cancer research highlighted the benefits of GE from both tumor and non-tumor microenvironment. GE and associated cell signaling pathways can provide broader, deeper and more accurate treatment insights far more than DNA mutation alone. GE make it possible to reveal mechanisms and pathways that regulate tumor growth, drug response, and interactions with immune system in ways that are not possible using DNA.
OncoDxRx’s OncoMRD makes it possible to test how solid tumors respond to drugs, immune cells, microenvironment, and genetic changes. These cfmRNA-derived GE patterns provide specific fingerprints of each patient’s tumor which could make them susceptible to certain cancer drugs so that appropriate medical strategies can be employed.
The groundbreaking OncoMRD technology will capture more representative signals from all stakeholders (not just DNA mutations within tumor) so it could faithfully monitor drug efficacy, recurrence and prognosis. This type of sensitive liquid biopsy test could significantly improve clinical outcome.
Cancer has touched the lives of almost everyone. Clinical development on the OncoMRD test will make significant impact in cancer management and further improve the quality life of each patient.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam